STUDIES ON CS-1170

• Published in: CHEMOTHERAPY Vol. 26; no. Supplement5; pp. 193 - 202
• Main Authors: MASHIMO, KEIMEI, KUNII, OTOHIKO, FUKAYA, KAZUFUTO, TANI, SHOKICHI, HARANAKA, KATSUYUKI, WATANABE, MICHIO, KOMATSU, TAKASHI, SATOMI, NOBUKO
• Format: Journal Article
• Language: Japanese
• Published: Japanese Society of Chemotherapy 25.10.1978
• ISSN: 0009-3165; 1884-5894
• DOI: 10.11250/chemotherapy1953.26.Supplement5_193

On a new cephamycin group antibiotic, CS-1170, several basic and clinical studies were performed and the following results were obtained. 1) The sensitivities to CS-1170 were determined about clinical isolates belonging to gram negative bacilli comparing with those to cefazolin (CEZ). In general the antibacterial activity of CS-I170 markedly exceeded that of CEZ. 2) The phase one study of CS-1170 was performed in our clinic. CS-1170 was administered in gradually increasing doses by three routes to a total of 24 volunteers, confirming the safety of this agent. 3) At above mentioned study, blood level, urinary recovery and metabolism were also investigated. The blood level rose relatively high, and sustained well. Urinary recovery was also high. There found no bioactive metabolite from urine. 4) The blood level in drip infusion of CS-1170 was compared with that of cefoxitin (CEX) and CEZ in cross over fashion. When standard curve was drawn by serial dilution of the drug using buffer, the blood level of CS-1170 was maintained in the highest value among them. 5) At a patient who had been built external biliary fistula, biliary excretion of CS-1170 was compared with that of CFX in cross over fashion. CS-1170 was superior to CFX in both of biliary level and excretion rate. 6) Clinically CS-1170 was administered to 7 patients with various infections. As a result, 4 were good, one was poor and 2 were impossible in judgement. No side effect was observed.